Stem Cell Stock Investor News Alert; Neuralstem (CUR) Gains over 42%

New York, New York - September 13, 2012 (Investorideas.com Newswire) - Investorideas.com, a leader in sector stock research including biotech stocks, issues a trading alert for stem cell stock Neuralstem, Inc. (NYSE MKT : CUR) , trading at $1.42, up $0.42 or 42.00% as of 11:41AM EDT on over 4 Million shares. The stock had a morning high of $1.46.
In the August 29, 2012 edition of the MicroCap Investor, analyst Josh Levine featured Neuralstem (CUR) as a strong buy at 50 cents. Josh told his subscribers "Neuralstem (CUR) is on a mission to develop unique therapies for some of the most challenging medical maladies faced by healthcare practitioners today. But its shares are valued extremely modestly by the market, suggesting one of two things - either CUR is falling short in its mission; or it has yet to gain sufficient recognition and credibility on the Street and among a wide investor audience. As you might guess, I definitely think it's the latter."
Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, and has been awarded orphan status designation by the FDA.
About Josh Levine's MicroCap Investor: http://www.levinesmicrocapinvestor.com

The strategy for MicroCap Investor is simple: to focus on small, innovative companies representing the best pure plays in the fast-growing waves of change in biotechnology, cleantech, and emerging IT.
MicroCap Disclaimer/disclosure - http://www.levinesmicrocapinvestor.com/disclosure/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and access our 13 online stock directories 24/7 - water, renewable energy, mining stocks and more…
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Biotech Stock Alert: SUNSHINE BIOPHARMA (OTCBB:SBFM) Advances to Next Phase of Drug Development with Lead Anti-Cancer Compound, Adva-27a

Montreal, Quebec, Canada - September 13, 2012 (Investorideas.com Newswire) Sunshine Biopharma Inc. (OTCBB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, reports recent progress which has enabled the Company to advance to the next phase of drug development, namely GMP manufacturing, IND-enabling studies and Phase I clinical trials in humans.

"We have made significant recent strides in terms of research results showing the effectiveness of our lead compound against cancer cells as well as in our manufacturing, and recent fund raising efforts," said Dr. Steve N. Slilaty, President and CEO of Sunshine Biopharma.
While Adva-27a has proven very effective in its ability to kill various types of cancer cells, the compound&'s most remarkable activity is against multidrug resistant cancer cells. The Company has previously reported that Adva-27a is particularly effective against Multidrug Resistant Breast Cancer cells (MCF-7/MDR) and Small-Cell Lung Cancer cells (H69AR).
The Company has also previously reported that Adva-27a has performed extremely well in a battery of preclinical tests. These tests have shown that:

• Adva-27a is unaffected by P-Glycoprotein, the enzyme responsible for making cancer cells resistant to anti-tumor drugs.
• Adva-27a has excellent clearance time (half-life = 54 minutes) as indicated by human microsomes stability studies.
• Adva-27a clearance is independent of Cytochrome P450, a mechanism that is less likely to produce toxic intermediates.
• Adva-27a is an excellent inhibitor of Topoisomerase II with an IC50 of only 13.7 micromolar.
• Adva-27a has shown excellent pharmacokinetics profile as indicated by studies done in rats.

The initial indication for Adva-27a&'s Phase I human trials will be multidrug resistant breast cancer for which there are little or no treatment options.
The Company has recently taken delivery of a new batch of Adva-27a from the Contract Manufacturing Organization (CMO) and now is proceeding to conduct a series of requisite biological tests to ensure that the newly manufactured batch is identical to the original, not only in terms of chemical structure but also in terms of biological activity.
The Company has recently raised $460,000 through a private offering of its Common Stock, with proceeds being used for manufacturing and other activities in preparation for Phase I clinical trials.
About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company&'s lead compound, Adva-27a targets aggressive forms of cancer.
www.sunshinebiopharma.com
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com
Published at Investorideas.com newswire
InvestorIdeas.com is a leader in investor stock research by sector, including biotech and pharma stocks. Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and biotech stock alerts
Research biotech stocks at the Investor Ideas Biotech stocks Directory
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26th
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Biotech Stock News; Aethlon Medical (OTCBB: AEMD) Discloses MD Anderson Cancer Center Presentation

SAN DIEGO - September 11, 2012 (Investorideas.com newswire) - Biodfense stock news; Aethlon Medical, Inc. (OTCBB: AEMD), disclosed this afternoon that its Chairman and CEO, Jim Joyce, and Chief Science Officer, Dr. Richard Tullis, gave a presentation yesterday at the MD Anderson Cancer Center in Houston, Texas. The presentation was entitled: The extracorporeal removal of tumor-secreted exosomes: An adjunct strategy to reverse immune suppression and inhibit metastases in melanoma.

The presentation focused on the potential of the Aethlon Hemopurifier® to be combined with chemo and immunotherapies as a strategy to improve melanoma treatment outcomes. The Hemopurifier®, which is a first-in-class device being advanced in Hepatitis C (HCV) care, has also demonstrated the ability to capture cancer-promoting exosomes secreted by tumors. Tumor-secreted exosomes have emerged to become a potentially vital therapeutic target in cancer as researchers have reported these microvesicular particles promote tumor progression by inducing programmed cell death of anti-cancer immune cells. As a result of inhibiting the immune response, exosomes increase the proliferation and spread of many forms of cancer. Researchers have also reported that exosomes seed the spread of metastasis, promote angiogenesis (essential for tumor survival and growth), increase tumor aggressiveness, and contribute to anti-cancer drug resistance.
"We are truly appreciative for the invitation that allowed us to share our vision for improving metastatic melanoma care with physicians and researchers at MD Anderson," stated Mr. Joyce.
The slide-deck of Aethlon's presentation can be accessed on the company's website at: http://aethlonmedical. investorroom.com/ index.php?s=19.

About MD Anderson Cancer Center
Over the past 70 years, The University of Texas MD Anderson Cancer Center has become the world's premier center devoted exclusively to the prevention, treatment and eradication of cancer through research. For eight of the past 10 years, MD Anderson has ranked No. 1 in cancer care in the "Best Hospitals" survey published by U.S. News & World Report. In fiscal year 2011, more than 108,000 people — about one-third of them new patients — sought the high-quality care that has made MD Anderson so widely respected. There were nearly 10,000 registrants on clinical trials exploring novel treatments, the largest such program in the nation.
About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs

Biotech Stock News; ThisweekinMedIT.tv features the Aethlon Medical Hemopurifier

SAN DIEGO - September 10, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), disclosed that ThisweekinMedIT.tv (TWIMIT) features an interview with Chairman and CEO, Jim Joyce regarding the Aethlon ADAPT™ system and Hemopurifier®. The interview can be accessed on the company's website.

Aethlon Medical also disclosed that the San Diego Business Journal (SDBJ) has published an article regarding the company's $6.8 million contract with the Defense Advanced Research Projects Agency (DARPA) to develop selective therapeutic filtration technology that would reduce the incidence of sepsis in wounded warfighters. The SDBJ article can be accessed on the company's website.
About ThisweekinMedIT.tv
ThisweekinMedIT.tv is a premier medical technology source that provides the up to date news focusing on the medical and IT industries. ThisweekinMEDIT.tv (TWIMIT) finds and reports the latest answers to the healthcare and technology questions, reports on location at the most talked about events and interviews news breaking medical companies. Bringing together creditable resources onto one site, TWIMIT works around the clock "digging deeper" on topics that are important to healthcare professionals.
About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs

Biotech Stock Trading Alert: Sunshine Biopharma (OTCBB: SBFM) Shares Gain over 12% on news of Delivery of Lead Anti-Cancer Compound Adva-27a

New York, New York - September 5, 2012 (Investorideas.com Newswire, www.biotechindustrystocks.com) Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks issues a trading alert for Sunshine Biopharma Inc. (OTCBB: SBFM) as of the close of trading September 4 th , following news that it has taken delivery of an initial batch of Adva-27a.

Now that the Company has taken delivery from the Contract Manufacturing Organization (CMO) it will proceed to conduct a series of requisite biological tests to ensure that the newly manufactured batch is identical to the original, not only in terms of chemical structure but also in terms of biological activity. Among the tests we will be performing are Topoisomerase II inhibition assays and cytotoxicity evaluations. The Topoisomerase II inhibition tests are already underway and the cytotoxicity evaluations will be initiated later this week. Adva-27a is Sunshine Biopharma's lead anti-cancer compound which has proven effective at killing Multidrug Resistant Breast Cancer cells (MCF-7/MDR) and Small-Cell Lung Cancer cells (H69AR).
Sunshine Biopharma's lead compound, Adva-27a, is an effective and highly specific Topoisomerase II (Top2) Inhibitor and has proven effective at killing Multidrug Resistant Breast Cancer cells (MCF-7/MDR) and Small-Cell Lung Cancer cells (H69AR).
Mr. Camille Sebaaly, CFO, previously commented as to the significance of this stage of drug development, "The Scale-up Manufacturing Protocol, the second part of the delivery from Beta Pharma Canada, will be confirmed by Sunshine Biopharma then transferred to the large-scale (over 1 kilogram range) manufacturer for large-scale process development and manufacturing under GMP conditions. The material produced under GMP condition will be used by Sunshine Biopharma to conduct IND-Enabling Studies and Phase I Clinical Trials in humans."
Read Investorideas.com First Q&A Interview with Mr. Camille Sebaaly, CFO
http://www.investorideas.com/CO/SBFM/news/2012/07021.asp
About Beta Pharma Canada
Beta Pharma Canada Inc. is an affiliate of Beta Pharma Inc. with offices and facilities in Connecticut (USA) and Shanghai ( China). Beta Pharma Canada Inc., headquartered in Montreal ( Canada), is a Canadian small-molecule drug discovery and manufacturing company specializing in design, synthesis and process development of novel pharmaceutical compounds.
About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company's lead compound, Adva-27a targets aggressive forms of cancer.
www.sunshinebiopharma.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, including biotech and pharma stocks. Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and biotech stock alerts
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26 th
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Biotech Stock Alert: SUNSHINE BIOPHARMA (OTCBB:SBFM) TAKES DELIVERY OF NEWLY MANUFACTURED BATCH OF Adva-27a AND PROCEEDS TO CONDUCTING BI0LOGICAL VERIFICATION OF THE COMPOUND'S ANTI-CANCER ACTIVITY

Montreal, Quebec, Canada - September 4, 2012 (Investorideas.com Newswire) Sunshine Biopharma Inc. (OTCBB:SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has taken delivery of an initial batch of Adva-27a from the Contract Manufacturing Organization (CMO) and has proceeded to conducting a series of requisite biological tests to ensure that the newly manufactured batch is identical to the original, not only in terms of chemical structure but also in terms of biological activity. Among the tests we will be performing are Topoisomerase II inhibition assays and cytotoxicity evaluations. The Topoisomerase II inhibition tests are already underway and the cytotoxicity evaluations will be initiated later this week. Adva-27a is Sunshine Biopharma’s lead anti-cancer compound which has proven effective at killing Multidrug Resistant Breast Cancer cells (MCF-7/MDR) and Small-Cell Lung Cancer cells (H69AR).

"We are delighted to have advanced to this stage in our Adva-27a development program", said Dr. Steve N. Slilaty, Sunshine’s President and CEO. “Biological testing is an important quality control procedure to ensure batch to batch identity in the manufacturing process”, he added.
About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company’s lead compound, Adva-27a targets aggressive forms of cancer.
www.sunshinebiopharma.com
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com
Published at the Investorideas.com newswire
InvestorIdeas.com is a leader in investor stock research by sector, including biotech and pharma stocks. Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and biotech stock alerts
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26 th
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Biotech Stock News; Aethlon Medical (OTCBB: AEMD) Discusses Therapeutic Device Strategies to Address Cancer, Hepatitis-C and Sepsis with the Wall Street Transcript

SAN DIEGO - August 23, 2012 (Investorideas.com newswire) - Biodfense stock news;Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the Wall Street Transcript has conducted an interview with its Chairman and CEO, Jim Joyce. The full interview is now available to be accessed online at: http://aethlonmedical. investorroom.com/ index.php?s=19.

About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs